Edward Uchio, MD
Urology · Orange, CANPI 1588648570
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $635,006 of the $848,638 with a category attached, or 74.8%. 30 manufacturers reported payments, led by Pfizer at 40.3% of the total. Reporting peaked in 2023 at $214,747 and has fallen 59.8% since, to $86,373 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 804 payments — averaging $1055.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$342K
- Astellas Pharma US Inc$227K
- Bayer$90K
- AstraZeneca$71K
- Merck$36K
- Progenics Pharmaceuticals, Inc.$30K
- plus $53K from 24 others
Across 1,629 payments — averaging $12,450 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$6.1M
- Medivation LLC.$5.4M
- Merck$5M
- Janssen Research & Development, LLC$787K
- Blue Earth Diagnostics$614K
- Bayer$478K
- plus $2M from 14 others
What the payments were for
- Consulting fees$37,4704%
- Speaking & faculty fees$635,00675%
- Travel & lodging$154,61218%
- Food & beverage$21,5153%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 320 | $341,656 |
| Astellas Pharma US Inc | 171 | $227,123 |
| Bayer | 74 | $90,101 |
| AstraZeneca | 58 | $70,587 |
| Merck | 26 | $35,882 |
| Progenics Pharmaceuticals, Inc. | 28 | $30,153 |
| Johnson & Johnson | 14 | $11,246 |
| Sanofi | 7 | $8,221 |
| Ferring Pharmaceuticals Inc. | 9 | $8,192 |
| Histosonics, Inc. | 12 | $4,026 |
| Blue Earth Diagnostics | 4 | $3,390 |
| Novartis | 6 | $3,318 |
| Janssen Scientific Affairs, LLC | 8 | $2,132 |
| Angiodynamics, Inc. | 11 | $1,949 |
| Ferring Pharmaceuticals AS | 5 | $1,874 |
| Exelixis Inc. | 8 | $1,858 |
| Astellas Pharma Global Development | 1 | $1,550 |
| Janssen Research & Development, LLC | 5 | $1,486 |
| Medivation LLC. | 1 | $1,156 |
| EDAP Technomed Inc | 2 | $704 |
| Myriad Genetic Laboratories, Inc. | 2 | $538 |
| BD | 5 | $343 |
| Calyxo, Inc. | 3 | $226 |
| Rochester Medical Corporation | 12 | $168 |
| Koelis Inc. | 1 | $157 |
| Telix Pharmaceuticals | 1 | $149 |
| Dendreon Pharmaceuticals LLC | 3 | $149 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $129 |
| Profound Medical Corp. | 1 | $98 |
| Fujifilm Healthcare Americas Corporation | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$848,638 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 49 | $665,459 |
| NubeqaDarolutamide | 37 | $459,032 |
| OrgovyxRelugolix | 119 | $298,312 |
| Abiraterone Acetate | 53 | $226,896 |
| MyrbetriqMirabegron | 11 | $11,656 |
| Dutasteride | 32 | $2,453 |
| Tamsulosin Hcl | 60 | $806 |
| Finasteride | 47 | $544 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $227 |
| Prednisone | 25 | $122 |
| Ciprofloxacin Hcl | 16 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $227,123 | $677,11560 claims |
| BayerNubeqa | $90,101 | $459,03237 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,132 | $226,89653 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Orange
- Jaime LandmanOrange$657K
- Ralph ClaymanOrange$523K
- Faysal YafiOrange$335K
- Bela DenesOrange$235K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.